+91-8668442535
Home / Biotechnology / Plasma Fra

Plasma Fractionation Market By Product (Coagulation Factor Concentrates, Immunoglobulin, Albumin, Protease Inhibitors and Others), By Application (Neurology, Immunology, Hematology, Critical Care and Others) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

The plasma fractionation market is expected to grow at a compound annual growth rate (CAGR) of 7.1% from 2018 to 2026, from US$ 18,099.5 million in 2017 to US$ 33,386.6 million by 2026. Plasma fractionation is utilized for obtaining large quantities of purified protein from human plasma. Researchers have been focusing diligently on understanding the role and significance of plasma-derived proteins in treating chronic ailments and autoimmune diseases. Increasing demand for biologics and increasing healthcare expenditure for drug development activities together drive the plasma fractionation market's growth.

The rising prevalence of autoimmune disorders and technical innovation in deriving highly purified proteins from human plasma drive the immunoglobulin market's growth.

Immunoglobulins are the market's dominant product segment in plasma fractionation. Technical innovations in deriving highly purified proteins from human plasma and the rising prevalence of autoimmune disorders drive the immunoglobulin market's growth. They are primarily composed of five classes (D, G, M, A, and E) and several subclasses that are responsible for immune system consolidation. Albumin is gaining huge attention among researchers owing to its drug-binding properties and its effective use as a formulating drug agent, medical device coating, surgery sealant, and vaccine ingredient.

Increasing morbidity and a lack of effective biological treatment drive the neurology applications market's growth.

According to the World Health Organization (WHO), approximately 450 million people are reported to be suffering from mental illness each year. Neurology is dominating the application segment for the plasma fractionation market. The chief attributes governing its market growth are increasing morbidity and the lack of effective biological treatment for neurological disorders. Recently, newer antibodies have been developed to hinder the process of protein cluster misfolding, which causes Alzheimer's and Parkinson's diseases. Immunology applications will be the fastest-growing segment in the near future owing to the significant rise in immunocompromised patients and technological advancements in the development of immunoglobulin to counteract disease manifestations associated with immunosuppression.

The increasing number of patients suffering from chronic diseases and the presence of state-of-the-art healthcare infrastructure drive market growth in North America.

North America is the supreme leader in the global plasma fractionation market, representing 38% of its share. The dominance is attributed to major factors such as the increasing number of patients suffering from chronic diseases and the presence of state-of-the-art healthcare infrastructure. As per the statistics provided by the Centers for Disease Control and Prevention (CDC), 1 in every 6 Americans is living with a chronic disease.

Europe holds a 25% market share owing to the existence of key players such as Biotest AG, Sanquin, Octapharma AG, and Grifols S.A. and the supportive regulatory environment provided by the European Medical Agency (EMA). Asia Pacific is responsible for 17% of the market's share and will showcase impressive growth during the forecast period on account of a rise in per capita income and an affordable reimbursement scenario for plasma fractionation products utilized during the treatment of chronic ailments.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026,considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The market is segmented by product, application, and geography.

Biopharmaceuticals actively engaged in providing plasma fractionation products are Baxter International, Inc., Biotest AG, CSL Limited, Grifols, S.A., Green Cross Corporation, Japan Blood Products Organization, Kedrion Biopharma, Inc., Octapharma AG, Sanquin, and Shire, Plc.

Key questions are answered in this report.

  • What are the latest inorganic and organic market growth strategies adopted in the plasma fractionation market?
  • Which biopharmaceutical companies are providing plasma-fractionated products for treating chronic ailments?
  • What are the latest technical innovations associated with human plasma protein purification?
  • What is the clinical use of immunoglobulin?
  • What are the prevalence rate of neurological disorders and their treatment using antibodies?
  • What is the growth rate of the plasma fractionation market in developing countries such as Asia Pacific, Latin America, the Middle East, and Africa? 

Frequently Asked Question:

The market for Plasma Fractionation Market is expected to reach USD$ 33,386.6 Mn in 2026.

The Plasma Fractionation Market is expected to see significant CAGR growth over the coming years, at 7.1%

The report is forecasted from 2018 -2026.

The base year of this report is 2017.

Biotest AG, CSL Limited, Grifols, S.A., Green Cross Corporation, Japan Blood Products Organization, Kedrion Biopharma, Inc., Octapharma AG are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Mar 2019
Category:  Biotechnology
Report ID:   59635
Report Format:   PDF
Pages:   120
Rating:    4.2 (69)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support